title: Autotransplantation of peripheral blood stem cells mobilized by G-CSF in hematological malignancies: evidence for rapid and long-term sustained hematopoietic reconstitution.
abstract: We assessed the ability of granulocyte colony-stimulating factor (G-CSF) to mobilize peripheral blood stem cells (PBSC), the efficacy of PBSC infusion in the rescue of hematopoiesis after high-dose chemotherapy in 22 adult patients with hematological malignancies, and the long-term quality of engraftment. Bolus subcutaneous injections of G-CSF (12 micrograms/kg/day) were administered for 6 days. A median of three leukaphereses resulted in the collection of a median of 5.45 X 10(8) mononuclear cells/kg, 4.52 X 10(6) CD34+ cells/kg, and 3.97 X 10(4) CFU-GM/kg. G-CSF (5 micrograms/kg daily) was administered after PBSC infusion until granulocyte recovery. The median time to attain a neutrophil level > 0.5 X 10(9)/L and a platelet count > 20 X 10(9)/ L was 11 days. The median follow-up in 17 survivors was 23.8 months. These patients have maintained a complete and stable graft and some of them with neoplastic recurrence tolerated further chemotherapy. These results confirm that mobilization of PBSC by G-CSF can be performed on an outpatient setting and used in heavily pretreated patients. G-CSF mobilized PBSC transplantation provides early and complete engraftment in most patients.
authors.affiliation: Division of Hematology and Hemotherapy, Hospital Universitario San Carlos, Universidad Complutense, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Díaz-Mediavilla
authors.forename: L
authors.initials: L
authors.lastname: Llorente
authors.forename: R
authors.initials: R
authors.lastname: Martínez
authors.forename: A
authors.initials: A
authors.lastname: Alvarez-Carmona
authors.forename: J
authors.initials: J
authors.lastname: Jordá
authors.forename: E
authors.initials: E
authors.lastname: Del Potro
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: D
authors.initials: D
authors.lastname: Morales
authors.forename: S
authors.initials: S
authors.lastname: Asenjo
authors.forename: M
authors.initials: M
authors.lastname: Fariñas
authors.forename: I
authors.initials: I
authors.lastname: Sáez
authors.forename: A
authors.initials: A
authors.lastname: Villegas
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor